Drugs that contain Ethinyl Estradiol; Levonorgestrel
1. List of Balcoltra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7838042 | AVION PHARMS | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Jun, 2027
(3 years from now) | |
Market Authorisation Date: 09 January, 2018
Treatment: Administration of ferrous bisglycinate tablets
Dosage: TABLET;ORAL
BALCOLTRA family patents
2
United States
1
Germany
1
European Union
2. List of Loseasonique drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(11 days from now) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(19 days from now) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(5 years from now) | |
Market Authorisation Date: 24 October, 2008
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
LOSEASONIQUE family patents
18
United States
7
New Zealand
6
Japan
5
Canada
5
European Union
4
Australia
3
Russia
3
China
2
Spain
2
Hong Kong
2
Brazil
2
South Africa
2
Hungary
1
Luxembourg
1
Israel
1
Denmark
1
Cyprus
1
Bulgaria
1
Portugal
1
Poland
1
Slovenia
1
Mexico
3. List of Quartette drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450299 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Oct, 2025
(2 years from now) | |
| US8415332 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Mar, 2029
(5 years from now) | |
Market Authorisation Date: 28 March, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
QUARTETTE family patents
8
United States
4
European Union
2
Canada
2
Mexico
2
Brazil
2
China
2
Japan
2
Taiwan
1
Argentina
1
Australia
1
Israel
1
Russia
1
Korea, Republic of
4. List of Seasonique drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(11 days from now) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(19 days from now) | |
| US7320969 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jan, 2024
(7 months from now) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(5 years from now) | |
Market Authorisation Date: 25 May, 2006
Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
SEASONIQUE family patents
18
United States
7
New Zealand
6
Japan
5
Canada
5
European Union
4
Australia
3
Russia
3
China
2
Spain
2
Hong Kong
2
Brazil
2
South Africa
2
Hungary
1
Luxembourg
1
Israel
1
Denmark
1
Cyprus
1
Bulgaria
1
Portugal
1
Poland
1
Slovenia
1
Mexico
5. List of Twirla drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9050348 | AGILE | Dermal delivery device |
Jul, 2028
(5 years from now) | |
| US8747888 | AGILE | Dermal delivery device with in situ seal |
Jul, 2028
(5 years from now) | |
| US8246978 | AGILE | Dermal delivery device with reduced loss of its volatile components |
Aug, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 14, 2023 |
Market Authorisation Date: 14 February, 2020
Treatment: NA
Dosage: SYSTEM;TRANSDERMAL
TWIRLA family patents
15
United States
2
Japan
2
European Union
1
Canada
1
Georgia
1
Brazil
1
China
1
New Zealand
1
Australia
1
EA
1
Spain
1
Hong Kong
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic